‘Jardiance’ entering insurance benefit will expand SGLT-2 inhibitor market with Forxiga
Followed by AstraZeneca’s Forxiga and Astellas’s Suglat, Boehringer Ingelheim’s Jardiance entered the health insurance benefit door for the third time as a SGLT-2 inhibitor.
The last year’s prescriptions of Forxiga, exceeding KRW 10 billion, has brought a huge impact. The increase was explosive ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
